Navigation Links
Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
Date:4/24/2008

ALLEGAN, Mich., April 24 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) Nicotine Polacrilex Gum USP, 2 mg (base) and 4 mg (base) (Orange, Coated).

The FDA has determined the product to be bioequivalent to the reference listed drug, GlaxoSmithKline's Nicorette(R) Gum, 2 mg (base) and 4 mg (base), which is an aid to smoking cessation. "This approval of orange-flavored, coated nicotine gum extends our leading store brand position. Our expanded range of smoking cessation products also includes coated mint-flavored gum, coated fruit-flavored gum, uncoated gum and lozenges," said Joseph C. Papa, Perrigo's Chairman and CEO. The overall market for OTC nicotine gum and lozenge products is estimated at approximately $750 million annually at all retail outlets.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet ( http://www.perrigo.com ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
2. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
3. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
4. Perrigo Company Announces Launch of Clobetasol Propionate Foam
5. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
6. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
7. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
8. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
9. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... , ... Sideline Products is a Southern York County Pennsylvania-based premier designer and ... the horse. Smaller saddles can pinch and irritate the horse creating safety issues and ... fitted western saddle so it does not impact the comfort or performance of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Airy Jeanine ... with prolific Songwriter-Producer Corey “Chorus” Gibson who has worked on hits by mega-artists ... a few.     https://twitter.com/coreychorus , The sessions taking place in North Jersey’s ...
(Date:12/5/2016)... ... , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and Dr. Douglas ... not do their research and undergo cosmetic dermatology treatments from unqualified practitioners or worse, ... renaissance and every other month a new treatment or device is launched, promising everlasting ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016  New research by the ... Institute and the U.S. Department of Health and ... Preparedness and Response (ASPR), published online today in ... pharmacy notifications encourage patients with chronic conditions to ... The study also affirms that public-private partnerships can ...
(Date:12/5/2016)... Dec. 5, 2016  BD (Becton, Dickinson and Company) ... technology company, will demonstrate an enhanced technology platform designed ... including the company,s leading Pyxis™ and Alaris™ systems, at ... 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent of ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... , , The global ... by 2021, at a CAGR of 5.3% from 2016 to 2021. Factors ... obesity cases, increasing government spending on healthcare, and rising income levels are ...
Breaking Medicine Technology: